Biotech Pest Management

biotechpestmanagement.com

Biotech Pest Management is a Charleston, South Carolina exterminator specializing in pest control services for residential and commercial property; including bed bug, mosquito and wildlife management.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

BIOAGE PARTNERS WITH AGE LABS TO DECIPHER HEALTHY LONGEVITY USING SAMPLES AND DATA FROM A PREEMINENT NORTHERN EUROPEAN BIOBANK

BioAge Labs, Inc. | August 24, 2022

news image

BioAge Labs, Inc. a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that it has initiated a partnership agreement with Age Labs AS a diagnostic company that develops tests for the early detection of age-related diseases. Under the terms of the agreement, BioAge will perform multi-omics analyses on samples and health records from the Nord-Trøndelag Health Study biobank collected from more than 100,000...

Read More

Industrial Impact

FOUR NEW SETS OF PRE-CLINICAL DATA FURTHER EXPANDS THE EVIDENCE SUPPORTING ABELACIMAB

Anthos Therapeutics | July 14, 2022

news image

Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, announced that four new research updates were presented on abelacimab during the Venous Thromboembolism poster session at the ongoing International Society on Thrombosis and Haemostasis 2022 Congress in London, UK. "Coagulation is a complex multilayered process and the potential benefits of inhibiting Factor XI are becomi...

Read More

Cell and Gene Therapy

CURI BIO CLOSES $10M SERIES A IN OVERSUBSCRIBED ROUND

Curi Bio Inc. | December 30, 2021

news image

Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced the second closing of a $10 million oversubscribed Series A financing. New investors include UTC Investment and DS Asset Management, joining current Curi Bio investor and Series A lead Dynamk Capital. The investment will be used to scale Curi’s existing business and accelerate the development of its innovative engineered tissue analysis platforms, including its Mantarray™ platform.
Read More

MedTech

LIGAND PHARMACEUTICALS SELECTS LANDING AI'S LANDINGLENS VISUAL INSPECTION SOFTWARE PLATFORM TO ENHANCE THE ANTIBODY DISCOVERY PLATFORMS

Ligand Pharmaceuticals | July 29, 2021

news image

Landing AI announced today that it has entered into a software licensing deal with Ligand Pharmaceuticals Incorporated to integrate LandingLens into Ligand's OmniAb and xPloration antibody discovery platforms. LandingLens is a software platform that offers an end-to-end process for developing, experimenting and delivering AI-powered visual inspection solutions. The new AI-powered tools enhance Ligand's high-throughput single B cell screening accuracy and throughput in a wi...

Read More
news image

MedTech

BIOAGE PARTNERS WITH AGE LABS TO DECIPHER HEALTHY LONGEVITY USING SAMPLES AND DATA FROM A PREEMINENT NORTHERN EUROPEAN BIOBANK

BioAge Labs, Inc. | August 24, 2022

BioAge Labs, Inc. a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that it has initiated a partnership agreement with Age Labs AS a diagnostic company that develops tests for the early detection of age-related diseases. Under the terms of the agreement, BioAge will perform multi-omics analyses on samples and health records from the Nord-Trøndelag Health Study biobank collected from more than 100,000...

Read More
news image

Industrial Impact

FOUR NEW SETS OF PRE-CLINICAL DATA FURTHER EXPANDS THE EVIDENCE SUPPORTING ABELACIMAB

Anthos Therapeutics | July 14, 2022

Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, announced that four new research updates were presented on abelacimab during the Venous Thromboembolism poster session at the ongoing International Society on Thrombosis and Haemostasis 2022 Congress in London, UK. "Coagulation is a complex multilayered process and the potential benefits of inhibiting Factor XI are becomi...

Read More
news image

Cell and Gene Therapy

CURI BIO CLOSES $10M SERIES A IN OVERSUBSCRIBED ROUND

Curi Bio Inc. | December 30, 2021

Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced the second closing of a $10 million oversubscribed Series A financing. New investors include UTC Investment and DS Asset Management, joining current Curi Bio investor and Series A lead Dynamk Capital. The investment will be used to scale Curi’s existing business and accelerate the development of its innovative engineered tissue analysis platforms, including its Mantarray™ platform.
Read More

news image

MedTech

LIGAND PHARMACEUTICALS SELECTS LANDING AI'S LANDINGLENS VISUAL INSPECTION SOFTWARE PLATFORM TO ENHANCE THE ANTIBODY DISCOVERY PLATFORMS

Ligand Pharmaceuticals | July 29, 2021

Landing AI announced today that it has entered into a software licensing deal with Ligand Pharmaceuticals Incorporated to integrate LandingLens into Ligand's OmniAb and xPloration antibody discovery platforms. LandingLens is a software platform that offers an end-to-end process for developing, experimenting and delivering AI-powered visual inspection solutions. The new AI-powered tools enhance Ligand's high-throughput single B cell screening accuracy and throughput in a wi...

Read More